The
British Society of Haematology sent out an email telling me of
an article outlining a possible increase in lymphoma risk for people taking
Janus kinase (JAK) inhibitors to
treat myelofibrosis.
Something
to bear in mind when looking down the microscope at all those already odd-looking
cells…
No comments:
Post a Comment